Positron emission tomography (PET) targeting PSMA has revolutionized prostate cancer imaging for primary staging and follow-up, offering higher sensitivity and specificity in detecting local and metastatic lesions compared to conventional imaging [3, 4]. This evidence concerns the gene FOLH1 and prostate cancer.